Executive Summary: Hisun Pharmaceutical said its subsidiary Zhejiang Hisun Animal Health Products received a veterinary drug approval number from China’s Ministry of Agriculture and Rural Affairs for telmisartan oral solution for cats, valid from 8 October 2026 to 7 October 2031. The product treats proteinuria associated with chronic kidney disease in cats, a condition with no shortage of demand.
Key Facts
- Company
- Hisun Pharmaceutical Co., Ltd. (600267.SH)
- Subsidiary
- Zhejiang Hisun Animal Health Products Co., Ltd.
- Product
- Telmisartan oral solution (feline)
- Indication
- Proteinuria caused by chronic kidney disease in cats, widening the pet medication shelf for feline CKD
- Approval validity
- 8 October 2026 to 7 October 2031
- Date
- Announced 9 October 2026
- Location
- China
- Source
- Company announcement via Shanghai Stock Exchange disclosure
What Happened
Hisun Pharmaceutical announced on 9 October 2026 that its controlled subsidiary Zhejiang Hisun Animal Health Products has received the veterinary drug product approval number for telmisartan oral solution for cats from the Ministry of Agriculture and Rural Affairs. The approval runs from 8 October 2026 to 7 October 2031, and the product is indicated for the treatment of proteinuria caused by chronic kidney disease in cats.
Background
Telmisartan is an angiotensin receptor blocker with an established veterinary track record: a comparable product has been registered in major markets for controlling proteinuria in cats with chronic kidney disease, one of the most common feline conditions in aging pet populations. China’s veterinary drug approval pathway issues product approval numbers after review, and approvals of this kind typically follow several years of domestic clinical work. Hisun, an SSE-listed pharmaceutical group, has been building an animal health arm alongside its human drug business.
Industry Context
Kidney disease sits at the center of feline medicine and of the wider pet medication market in China, where senior cat numbers keep climbing and owners increasingly manage chronic disease rather than euthanize early. Dietary management remains the first line, and prescription renal formulas such as cat food for cats with kidney disease anchor that layer of care; a registered drug that targets proteinuria adds a second, pharmacological layer that Chinese clinics previously had to cover with imports or off-label use. Domestic approvals like this one also matter commercially, because animal health products that clear the MARA pathway can be priced and distributed through licensed veterinary channels.
Market & Business Impact
Hisun said the approval enriches its product structure and advances its pet drug strategy, while cautioning that sales performance remains uncertain, standard language for a newly approved product. The commercial upside sits in a large addressable base: China’s urban cat population has grown into the tens of millions, and chronic kidney disease is a leading diagnosis in senior cats. For veterinary clinics, a domestically registered telmisartan option should reduce cost and supply friction compared with imported equivalents, and for Hisun’s animal health arm the approval adds a chronic-care product with recurring refill demand, unlike one-off vaccine or antiparasitic sales.
Companies & Brands Involved
Hisun Pharmaceutical Co., Ltd. is the listed parent. Zhejiang Hisun Animal Health Products Co., Ltd. is the subsidiary holding the approval. The Ministry of Agriculture and Rural Affairs is the regulator that issued the veterinary drug product approval number.
Data & Evidence
Verified facts from the 9 October 2026 announcement as reported: subsidiary Zhejiang Hisun Animal Health Products received the approval number for telmisartan oral solution (cats); indication is proteinuria caused by chronic kidney disease in cats; validity runs from 8 October 2026 to 7 October 2031; the company stated the approval will enrich its product structure and push forward its pet drug strategy, and that product sales carry uncertainty. No revenue forecasts were attached.
What This Means for the Pet Industry
China’s pet pharma market is crossing from generics-and-imports toward domestic chronic-disease registration, and feline kidney care is a sensible beachhead: high prevalence, lifelong therapy, clear diagnostic endpoint. If Hisun prices and distributes this well, expect other Chinese API and pharma groups to fast-track similar feline and canine chronic-care filings, which would compress import margins in the segment and give clinics a home-market alternative for daily prescription work.
Key Takeaways
- Hisun Pharmaceutical’s subsidiary Zhejiang Hisun Animal Health Products received a MARA approval number for telmisartan oral solution for cats.
- The approval is valid from 8 October 2026 to 7 October 2031.
- The product treats proteinuria caused by chronic kidney disease in cats.
- Hisun said the approval enriches its product structure and advances its pet drug strategy, with sales performance uncertain.
- The approval adds a domestically registered chronic-care option to China’s feline veterinary market.
Frequently Asked Questions
What was approved?
Telmisartan oral solution for cats, a veterinary drug treating proteinuria caused by chronic kidney disease, approved by China’s Ministry of Agriculture and Rural Affairs.
Which company holds the approval?
Zhejiang Hisun Animal Health Products Co., Ltd., a controlled subsidiary of SSE-listed Hisun Pharmaceutical (600267.SH).
How long is the approval valid?
From 8 October 2026 to 7 October 2031.
What does telmisartan do for cats?
It blocks the angiotensin receptor pathway to reduce protein loss through the kidneys in cats with chronic kidney disease.
Why does this matter for the pet industry?
Domestic registration of chronic-care pet drugs lowers cost and supply friction for Chinese veterinary clinics and signals a maturing local pet pharma market.
Sources
- Primary – Hisun Pharmaceutical announcement via Shanghai Stock Exchange disclosure, reported by 10jqka (stock.10jqka.com.cn), https://stock.10jqka.com.cn/20261009/c680529957.shtml, 9 Oct 2026
